Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. [electronic resource]
Producer: 20150505Description: 1567-73 p. digitalISSN:- 1791-7530
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Camptothecin -- administration & dosage
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Everolimus
- Female
- Humans
- Irinotecan
- Male
- Middle Aged
- Mutation
- Neoplasm Metastasis
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Sirolimus -- administration & dosage
- ras Proteins -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.